Opioid Use Disorder Market: Market Trends and Future Outlook 2024-2032
The global Opioid Use Disorder (OUD) market is experiencing substantial growth, driven by increasing opioid addiction rates and enhanced governmental initiatives. According to a report by SNS Insider, the market was valued at USD 3.7 billion in 2023 and is projected to reach USD 9.02 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.4% during the forecast period from 2024 to 2032.
Market Overview
The alarming rise in opioid-related fatalities has underscored the urgent need for effective OUD treatments. In 2022, over 108,000 individuals in the United States succumbed to drug-involved overdoses, encompassing both illicit and prescription drugs. This escalating crisis has catalyzed significant legal actions against pharmaceutical companies, exemplified by Purdue Pharma and the Sackler family's $7.4 billion settlement addressing their role in the opioid epidemic.
Regional Analysis
North America leads the OUD market, attributed to the high prevalence of opioid addiction and proactive governmental interventions. The Biden-Harris administration's allocation of over $450 million in August 2023 to combat the overdose epidemic aims to expand prevention, treatment, and recovery services. Europe and Asia-Pacific regions are also witnessing growth, propelled by increasing awareness and the implementation of supportive healthcare policies.
Get Free Sample Report @ https://www.snsinsider.com/sample-request/3018
Market Segmentation
The OUD market is segmented based on drug class, route of administration, and distribution channel:
- By Drug Class: Medications such as methadone, buprenorphine, and naltrexone are commonly used in treatment protocols.
- By Route of Administration: Treatment options include oral administration, injectable administration, and others.
- By Distribution Channel: Availability spans across hospital pharmacies, retail pharmacies, and online pharmacies.
Key Players
Service Providers / Manufacturers
- Indivior PLC (Sublocade, Suboxone)
- Alkermes plc (Vivitrol, Aristada)
- Purdue Pharma L.P. (Hysingla ER, Butrans)
- Braeburn Pharmaceuticals (Brixadi, Probuphine)
- BioDelivery Sciences International, Inc. (Belbuca, Bunavail)
- Titan Pharmaceuticals, Inc. (Probuphine Implant, ProNeura)
- Teva Pharmaceutical Industries Ltd. (Buprenorphine, Naloxone Tablets)
- Camurus AB (Buvidal, Episil Oral Liquid)
- Mallinckrodt Pharmaceuticals (Methadose, Roxicodone)
- Orexo AB (Zubsolv, Abstral)
Key Market Drivers
- Escalating incidence of opioid addiction globally.
- Enhanced government involvement and funding promoting awareness and preventive programs.
- Innovations such as buprenorphine patches offering effective treatment modalities.
Future Outlook
The OUD market is anticipated to expand further, driven by ongoing governmental initiatives, increased funding, and the development of innovative treatment options. The integration of Medication-Assisted Treatment (MAT) as a core strategy in OUD management is expected to enhance treatment accessibility and efficacy, thereby reducing the global burden of opioid addiction.
Conclusion
The escalating opioid crisis necessitates comprehensive and effective treatment solutions. The projected growth of the OUD market reflects a global commitment to addressing this public health challenge through enhanced treatment accessibility, innovative therapies, and robust governmental support.
Contact Us:
Jagney Dave - Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Other Related Reports:
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian